Scarica l'app Stockscreener
1.95
8.33%
0.15
Pre-mercato:
1.97
0.02
+1.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial - Traders Union
[SCHEDULE 13G] Ocugen, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Ocugen (OCGN) up 2.9% since last earnings report: Can it continue? - MSN
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
OCGN Forecast, Price Target & Analyst Ratings | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen's Financial Lifeline Fuels High-Stakes Gene Therapy Push - AD HOC NEWS
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Stock Receives 'Moderate Buy' Rating from Analysts - National Today
Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
OCU410 shows nearly double treatment effect over approved therapies, Ocugen, Inc. asserts - Traders Union
Ocugen's Gene Therapy Ambitions Fueled by Clinical and Financial Milestones - AD HOC NEWS
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Benzinga
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
Ocugen Secures Financial Runway as Gene Therapy Pipeline Accelerates - AD HOC NEWS
Ocugen (OCGN) price target increased by 11.43% to 11.37 - MSN
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial - MyChesCo
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Pharma News: Will Ocugen Inc stock recover after earningsTreasury Yields & Community Consensus Picks - baoquankhu1.vn
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Aug Macro: Is Ocugen Inc undervalued by DCF analysisWeekly Stock Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Q1 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - Yahoo Finance
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - investing.com
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - bitget.com
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - za.investing.com
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
$Ocugen (OCGN.US)$ - Moomoo
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - gurufocus.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - marketscreener.com
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 - GlobeNewswire
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN PE Ratio & Valuation, Is OCGN Overvalued - Intellectia AI
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data - insidermonkey.com
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):